oral BET inhibitor

4.5 mg QD, phase I/II for cancer

from bromodomain-focused HTS, SBDD

Journal of Medicinal Chemistry

Bristol Myers Squibb

The BMS BET inhibitor, BMS-986158, is in a Ph. I/IIa trial in advanced cancers. During the optimization of the molecule from a carbazole hit, the authors employed a bold scaffold-hopping…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.